Sign in

    Gautam Chukka • Evercore ISI

    Gautam Chukka is an Equity Research Analyst specializing in biotechnology at Evercore ISI, where he delivers in-depth equity coverage of leading biotech firms. With expertise in evaluating innovative biotechnology companies, he is recognized for rigorous company-specific research and analytical insight, although public sources do not provide trackable performance rankings or quantitative metrics for his buy/sell recommendations. Chukka began his career in biotech equity research prior to joining Evercore, building his profile as a sector specialist through roles focused on scientific and financial due diligence, yet specific dates and previous employer details are not publicly available. He holds key securities licenses and maintains registration with FINRA, establishing his credentials as a trusted equity research professional in life sciences.

    Gautam Chukka's questions to Spero Therapeutics Inc (SPRO) leadership

    Gautam Chukka's questions to Spero Therapeutics Inc (SPRO) leadership • Q2 2025

    Question

    Gautam Chukka of Evercore ISI asked about Spero's future capital allocation strategy, specifically whether the company would prioritize business development or internal pipeline investment.

    Answer

    CEO & CFO Esther Rajavelu stated that Spero's primary objective and capital focus is ensuring tebipenem HBr successfully navigates the regulatory process to approval, which is the key value driver. She confirmed the current cash runway supports this goal and that further capital allocation decisions would be made after gaining line of sight into the drug's approval.

    Ask Fintool Equity Research AI